Neurogene Stock Drops: Theravance Deal Shakes Market

viernes, 6 de junio de 2025, 3:08 pm ET1 min de lectura
NGNE--
TBPH--
Neurogene Inc. declined 3.05% in intraday trading. The recent news event involving Theravance BiopharmaTBPH--, Inc. and Mylan's settlement agreement may have influenced the market sentiment negatively, as Theravance Biopharma is a biopharma company focusing on developing and marketing medications, including YUPELRI for COPD treatment and Ampreloxetin for neurogenic orthostatic hypotension.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios